Moritz Reike

Former Postdoctoral Research Fellow @VanProstateCtr & @UBCUrology | Resident, Department of Urology, Marien Hospital Herne, Germany | Bladder Cancer

[Niklas Klümper @niklas_kluemper]

Thrilled to share our review published today in Nature Reviews Urology! @NatRevUrol: https://t.co/aWdhAXzTEy

"Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer"

Thanks to the amazing team of collaborators @AlexanderCoxMD @GottfridSjodahl @roghmann @ViktorGruenwald @FaltasLab @HolzelMichael @Markuseckstein3

We are exploring how real-time biopsies of metastases could capture the heterogeneity of met. UC, which could provide a clearer path to effective, targeted treatments for mUC!

#PrecisionOncology #UrothelialCancer #CancerResearch

@OncoAlert
#OncoAlertAF

@weoncologists @nataliagandur @acampsmalea @BiagioRicciutMD @yekeduz_emre @HHorinouchi
@FadiHaddad_MD @Dr_Ivanoncologo

@Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @lungoncdoc @bavilima @realbowtiedoc @Erman_Akkus @DrFMartinelli @Lucarecco

@matteolambe @Icro_Meattini @NarjustFlorezMD @double_whammied @JaniceTNBCmets @ARosen380 @kevinpunie @scserendipity1 @CathyEngMD @PGrivasMDPhD @tompowles1 @Uromigos @DrChoueiri @urotoday @DrYukselUrun @shilpaonc @PTarantinoMD

[Andrea Necchi, MD, FASCO @AndreaNecchi]

#PURE01 trial did it again! Distinct Gene Expression Patterns Identify Pts who Relapse After Neoadjuvant Pembro and RC. Neuroendocrine pattern worst outcome (to be excluded from IO trials) and zero relapses in Claudin-low subtypes @CMercinelli @BrigidaMaiorano @Anto_cigliola @vale_tateo @pcvblack
@ewanagibb @Davicioni @Decipher_VCYT @SanRaffaeleMI @MyUniSR https://t.co/ius777qZjm

[Niklas Klümper @niklas_kluemper]

Critical review of Nectin-4 in EV-302 vs. Literature needed!🧵

The recent findings from the EV-302 trial #ESMO24, demonstrating high Nectin-4 expression in almost all UC (median H-score >250) are in stark contrast with the literature, which were published independently of the EV development pipeline:

Contrary to studies by Challita-Eid (PMID: 27013195 - affiliated with the company that developed Enfortumab!) @CR_AACR @AACR, Chu et al. (PMID: 34108177) @CCR_AACR, and our own research @CCR_AACR, which demonstrated heterogeneous Nectin-4 expression in UC with absence of membranous Nectin-4 in the range of 20-40%, the EV302 trial's data again suggests a uniform high/ skewed expression of Nectin-4!

Membranous Nectin-4 expression correlates with EV response! https://t.co/bHbVqun45O. This aligns with observations from other ADCs, such as anti-HER2 ADCs, where target expression correlates with therapeutic efficacy. This correlation reflects a well-established biological principle!

This discrepancy raises concerns about the assumption that Nectin-4 is ubiquitously expressed in UC and underscores the need for careful interpretation!

Future treatment strategies for mUC (might) need to account for Nectin-4 status, potentially favoring alternative therapies like chemoimmunotherapy (JB100, CM901) or next-gen ADCs for patients with low or negative expression.

Happy to discuss the data with the community!
@ASCO @JCOPO_ASCO @OncoAlert @urotoday
@Markuseckstein3 @HolzelMichael @ViktorGruenwald
@KuppeChristoph @IEO_HolzelLab @drenriquegrande @PGrivasMDPhD @JoshMeeks @amerseburger @DrYukselUrun @tompowles1 @Uromigos @OncoBellmunt @montypal @DrChoueiri @neerajaiims @shilpaonc @sonpavde @DrRosenbergMSK @Dr_Aggen @jonchou05 @koshkin85 @Uroweb @PTarantinoMD @FAndreMD

[Markus Eckstein @Markuseckstein3]

It‘been a while, but 🎉🔬 The 17th episode is out.
The last entity we tackled was the „incarnation“ of hot/inflamed urothelial carcinomas🔥🔥🔥🔥

But what do you know about PD-L1 testing ?
Today @MattGalsky presented important data of CheckMate274 at #EAU24. PD-L1 positive patients benefit significantly from adjuvant Nivolumav treatment.
👉 In Europe adjuvant Nivolumab is only approved for PD-L1 positive patients.
👉 PD-L1 testing is thus important and its importance might increase with current neoadjuvant studies reading out soon!

But what does PD-L1 positive mean? Read below in following posts 👇

@AmerUrological, @Uroweb, @ASCO, @PathSoc. #Uropathology #urothelial #cancer #MedicalInnovation @NEJM @JAMANetwork @JAMA_current @OncoAlert @onkowissen @imedverse @Histo_Journal @niklas_kluemper #pathtwitter
@brookmans76 @PGrivasMDPhD @DrYukselUrun @shilpaonc @drenriquegrande @amerseburger

[Markus Eckstein @Markuseckstein3]

🌶️🌡️Summary of my uropathology for urologists and oncologists series! 👉check it out! and retweet if you like!
@urotoday @OncoAlert @Uroweb @EAUYAUrology @EAU_YAUroTech @EauPatient @niklas_kluemper @onkowissen

https://t.co/jC1aEhztgI

[Markus Eckstein @Markuseckstein3]

In the first part we tried to understand the architecture of regular urothelium and key markers expressed in different layers of it. This important to understand why urothelial cancer can appear with multiple molecular and histological subtypes.

[Markus Eckstein @Markuseckstein3]

Really grateful to have the opportunity presenting our work at #GU24 !! Genomic protein related biomarkers might be good correlated for precise smart targeted chemotherapies! @ASCO @urotoday @OncoAlert @shilpaonc @drenriquegrande @PGrivasMDPhD @ViktorGruenwald

[Alex Wyatt @ResearchWyatt]

Our latest study with @piet_ost, of whole prostates, lymph nodes, and ctDNA at initial diagnosis in de novo metastatic prostate cancer (distant mets) is out in @NatureCancer: https://t.co/6iMFs899iX. 1/n thread 👇

[Markus Eckstein @Markuseckstein3]

🔥Breaking News at #ESMO2023!🔥 EV302 is changing the game, unbelievable data (HR=0.45!!!) for metastatic urothelial cancer patients, really an evolution #EV302. Terrific presentation by @tompowles1. 🙌🔬🎗️ @urotoday @OncoAlert @myESMO

[Markus Eckstein @Markuseckstein3]

🔬 After years of relentless dedication two incredible minds have achieved a major scientific award @dgukongress ! Their journey in testis and urothelial cancer research is a testament to the power of collaboration and perseverance. @niklas_kluemper @tim_nestler @urotoday

[Gottfrid Sjödahl @GottfridSjodahl]

Our study dissecting the relationship between UC molecular subtypes and site specific metastasis out in @IntJCanc !

[Peter Black @pcvblack]

S1605 tested 12 months of atezolizumab in 74 patients with BCG unresponsive CIS±Ta/T1 and 55 patients with Ta/T1. There are many similarities with other trials in this space that were all designed based on early discussions between AUA/SUO/FDA – but also some key differences 1/n

[JAMA Oncology @JAMAOnc]

Integrating on-treatment mGPS (CRP + albumin) for a more holistic and patient-centered therapy monitoring in addition to radiological staging may improve outcome prediction for patients with mRCC. @saal_jonas @niklas_kluemper @IEO_HolzelLab @UniklinikBonn https://t.co/RJT2sc9IER

[Andrea Apolo, M.D. @apolo_andrea]

SWOG S1011: A phase III surgical trial evaluated standard vs an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive #urothelialcancer. No difference was seen between arms @ASCO #ASCO23

[Uromigos @Uromigos]

Paper of the month: @JoshMeeks develops 5 subgroups based on RNA signatures to predict response a PD(L)1 in urothelial cancer (figure bellow). Multiple mechanisms of response/resistant creates a complex picture which Josh simplifies . https://t.co/C26GZ31dYn

[Alexander Cox @AlexanderCoxMD]

Very pleased to share our latest work: Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution published in @EUPlatinum - https://t.co/mSy94Qc1sB - @niklas_kluemper @markuseckstein3. Follow our tweetorial about these clinically relevant data 1/9

[Gottfrid Sjödahl @GottfridSjodahl]

Superb session on biology of #MIBC this afternoon. Proteomics, organoids, and metastasis-profiling. Subtypes but not NECTIN4 stable in Mets. Also data on chemo/IO/erda response.

Discussions continued in the hall afterward but would have been even better with posters!! #EAU23

[Moritz Reike @moritzreike]

@pcvblack @VanProstateCtr @UBCUrology @BCCancer_GSC Thanks a lot, happy to be part of a great team in Vancouver!

[Peter Black @pcvblack]

Congratulations 👏👏 to #AlbertoContreras, @moritzreike and #GianLucaNegri for this award building on awesome team science #EAU23 @VanProstateCtr @UBCUrology @BCCancer_GSC

[Andrea Necchi, MD, FASCO @AndreaNecchi]

Congrats Moritz Reike and @Decipher_VCYT @ewanagibb for putting light on baseline features of patients relapsing after neoadjuvant Pembro and RC in #MIBC #PURE01 @ASCO @urotoday